Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 28

Sort by

Sort Order Select

Journal Articles

High levels of soluble TREM2 predict poor survival outcomes and facilitate the expansion of immunosuppressive monocytic-lineage cells in patients with DLBCL.

Hao-Yuan Wang, Po-Chun Liu, Fu-Chen Yang, Ching-Fen Yang, Chun-Kuang Tsai, Po-Shen Ko, Yao-Chung LIU, Nien-Jung Chen

Blood (2025) 146 (Supplement 1): 3659.

https://doi.org/10.1182/blood-2025-3659

Published: 2025

Journal Articles

Selinexor in combination with azacitidine or Ruxolitinib for Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes: A Multi-Center Prospective Exploratory Study

Xijuan Lin, Ziwei Liu, Chen Yang, Junling Zhuang, Na Wei, Tingting Cui, Wenqi Zheng, Fang Ye, Xiaoqing Ding, Miao Chen, Bing Han

Blood (2025) 146 (Supplement 1): 5624.

https://doi.org/10.1182/blood-2025-5624

Published: 2025

Journal Articles

Klippel-trenaunay syndrome with multifactorial anemia:successful management with sirolimus

Chen Yang

Blood (2025) 146 (Supplement 1): 6444.

https://doi.org/10.1182/blood-2025-6444

Published: 2025

Journal Articles

Efficacy and safety of bruton tyrosine kinase (BTK) inhibitor zanubrutinib in relapsed/refractory warm autoimmune hemolytic anemia (wAIHA) after multiple lines of therapy: A prospective phase 2 single-arm study

Miao Chen, Ziwei Liu, Chen Yang, Junling Zhuang, Bing HAN

Blood (2025) 146 (Supplement 1): 1104.

https://doi.org/10.1182/blood-2025-1104

Published: 2025

Journal Articles

Efficacy and safety of romiplostim N01 for refractory aplastic anemia: A retrospective single‑center study

Zhuang Qilin, Ziwei Liu, Chen Yang, Miao Chen, Junling Zhuang, Bing Han

Blood (2025) 146 (Supplement 1): 1416.

https://doi.org/10.1182/blood-2025-1416

Published: 2025

Journal Articles

KP104, a bifunctional C5 mAb–Factor h fusion protein, demonstrates sustained long-term efficacy and safety in complement inhibitor–naïve PNH patients: 2-year results from A phase 2 study with 8-week post-treatment safety follow-up.

Li Zhang, Chen Yang, Changhe Yue, Jay Ma, Chaomei He, Ping Tsui, Helen Fu, Angela Yan, Wenru Song, Fengkui Zhang, Bing Han

Blood (2025) 146 (Supplement 1): 1118.

https://doi.org/10.1182/blood-2025-1118

Published: 2025

Journal Articles

Correlation between efficacy, clonal dynamics evolution, and development of bone marrow failure in PNH/AA syndrome treated with complement inhibitors: A single-center cohort study

Chen Yang, Bing Han

Blood (2025) 146 (Supplement 1): 4987.

https://doi.org/10.1182/blood-2025-4987

Published: 2025

Journal Articles

VSA012, a CFB-targeted siRNA, demonstrates a favorable safety profile and sustained efficacy in PNH patients: Interim Analysis from a Phase Ib Study

Neng Nie, Chen Yang, Jun Shi, WANG Shunqing, Ruiqing Zhou, Hongyan Tong, Hong Chang, Dong You, Jin Chen, Jing Hao, Bing Han

Blood (2025) 146 (Supplement 1): 381.

https://doi.org/10.1182/blood-2025-381

Published: 2025

Journal Articles

Treatment with sirolimus for refractory/relapsed primary or secondary warm autoimmune hemolytic anemia/evans syndrome: A single centre prospective study

Qi Wang, Miao Chen, Junling Zhuang, Chen Yang, ziwei liu, Bing Han

Blood (2025) 146 (Supplement 1): 4666.

https://doi.org/10.1182/blood-2025-4666

Published: 2025

Journal Articles

Attenuated Levels of Surface TREM1 on Circulating Neutrophils Predict Poor Survival in Patients with Diffuse Large B-Cell Lymphoma before Treatment

Hao-Yuan Wang, Po-Chun Liu, Fu-Chen Yang, Yi-Ting Chen, Ching-Fen Yang, Chun-Kuang Tsai, Po-Shen Ko, Yao-Chung Liu, Nien-Jung Chen

Blood (2024) 144 (Supplement 1): 6273.

https://doi.org/10.1182/blood-2024-198810

Published: 2024

Journal Articles

Long-Term Real-World Follow-up Study of Luspatercept for Lower-Risk Myelodysplastic Neoplasms

Zhuxin Zhang, Leyu Wang, Ziwei Liu, Chen Yang, Miao Chen, Bing Han, Junling Zhuang

Blood (2024) 144 (Supplement 1): 6730.

https://doi.org/10.1182/blood-2024-199403

Published: 2024

Journal Articles

Effective Treatment of Refractory Aplastic Anemia with Romiplostim after Failure of Multiple Thrombopoietin Receptor Agonists: A Single-Center Retrospective Study

Xijuan Lin, Chen Yang, Ziwei Liu, Junling Zhuang, Miao Chen, Bing Han

Blood (2024) 144 (Supplement 1): 4077.

https://doi.org/10.1182/blood-2024-200421

Published: 2024

Journal Articles

A Phase I First-in-Human, Open-Label Trial to Investigate the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of SIM0500, a Humanized GPRC5D-BCMA-CD3 Trispecific Antibody, in Participants with Relapsed or Refractory Multiple Myeloma

Yan Xu, Zhen Cai, Zhongjun Xia, Chen Yang, Jia Chen, Zewen Zhu, Xiaojuan Jing, Ji Tian, Nating Zhang, Ailing Cui, Jianxing Tang, Haolin Sun, Lugui Qiu

Blood (2024) 144 (Supplement 1): 3381.2.

https://doi.org/10.1182/blood-2024-200737

Published: 2024

Journal Articles

KP104, a Bifunctional C5 Mab-Factor H Fusion Protein, Demonstrates Sustained Long-Term Efficacy and Safety in Complement Inhibitor-Naïve PNH Patients: Updated Results from a Phase 2 Study at 36/38 Weeks of Obd Treatment

Fengkui Zhang, Li Zhang, Chen Yang, Changhe Yue, Jay Ma, Chaomei He, Ping Tsui, Qing Yu Christina Weng, Helen Fu, Hui Yan, Wenru Song, Bing Han

Blood (2024) 144 (Supplement 1): 2699.

https://doi.org/10.1182/blood-2024-210086

Published: 2024

Journal Articles

Transcriptomic Profile of Peripheral Blood Mononuclear Cells in Sirolimus-Sensitive Acquired Pure Red Cell Aplasia Patients

Yuan Yang, Qinglin Hu, Chen Yang, Miao Chen, Junling Zhuang, Bing Han

Blood (2023) 142 (Supplement 1): 5199.

https://doi.org/10.1182/blood-2023-179897

Published: 2023

Journal Articles

Ratio of Circulating CD8 + T Lymphocytes to M-MDSCs (CD8MMR): A Novel Prognostic Predictor for Treatment-Naïve DLBCL Patients

Hao-Yuan Wang, Fu-Chen Yang, Ching-Fen Yang, Chun-Kuang Tsai, Po-Shen Ko, Yao-Chung Liu, Nien-Jung Chen

Blood (2023) 142 (Supplement 1): 1763.

https://doi.org/10.1182/blood-2023-178327

Published: 2023

Journal Articles

The Change of Complement Deposition after Complement Inhibitor Treatment in Paroxysmal Nocturnal Hemoglobinuria Patients

Menglu Zhang, Xuan Wang, Chen Yang, Miao Chen, Junling Zhuang, Bing Han

Blood (2023) 142 (Supplement 1): 1350.

https://doi.org/10.1182/blood-2023-178384

Published: 2023

Journal Articles

KP104, a Bifunctional C5 Antibody/Factor H Fusion Protein, Effectively Controls Both Intravascular and Extravascular Hemolysis: Interim Results from a Phase 2 Study in Complement Inhibitor-Naïve PNH Patients

Fengkui Zhang, Li Zhang, Chen Yang, Chunrong Wang, Changhe Yue, Hui Yan, Jay Ma, Helen Fu, Chaomei He, Ping Tsui, Jingtao Wu, Richard Lee, Wenru Song, Bing Han

Blood (2023) 142 (Supplement 1): 572.

https://doi.org/10.1182/blood-2023-186453

Published: 2023

Journal Articles

Rituximab Plus Bortezomib for Refractory and Relapsed Warm Autoimmune Hemolytic Anemia：a Prospective, Single-Arm, Phase Ⅱ Trial

Xijuan Lin, Chen Yang, Junling Zhuang, Daobin Zhou, Miao Chen, Bing Han

Blood (2023) 142 (Supplement 1): 3829.

https://doi.org/10.1182/blood-2023-178625

Published: 2023

Journal Articles

Myc Translocation Is an Adverse Factor Redefining High-Risk Multiple Myeloma

Xianghong Jin, Jianhua Du, Fujing Zhang, Hui Li, Shuangjiao Liu, Chen Yang, Miao Chen, Daobin Zhou, Junling Zhuang

Blood (2022) 140 (Supplement 1): 12575.

https://doi.org/10.1182/blood-2022-169332

Published: 2022

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

High levels of soluble TREM2 predict poor survival outcomes and facilitate the expansion of immunosuppressive monocytic-lineage cells in patients with DLBCL.

Selinexor in combination with azacitidine or Ruxolitinib for Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes: A Multi-Center Prospective Exploratory Study

Klippel-trenaunay syndrome with multifactorial anemia:successful management with sirolimus

Efficacy and safety of bruton tyrosine kinase (BTK) inhibitor zanubrutinib in relapsed/refractory warm autoimmune hemolytic anemia (wAIHA) after multiple lines of therapy: A prospective phase 2 single-arm study

Efficacy and safety of romiplostim N01 for refractory aplastic anemia: A retrospective single‑center study

KP104, a bifunctional C5 mAb–Factor h fusion protein, demonstrates sustained long-term efficacy and safety in complement inhibitor–naïve PNH patients: 2-year results from A phase 2 study with 8-week post-treatment safety follow-up.

Correlation between efficacy, clonal dynamics evolution, and development of bone marrow failure in PNH/AA syndrome treated with complement inhibitors: A single-center cohort study

VSA012, a CFB-targeted siRNA, demonstrates a favorable safety profile and sustained efficacy in PNH patients: Interim Analysis from a Phase Ib Study

Treatment with sirolimus for refractory/relapsed primary or secondary warm autoimmune hemolytic anemia/evans syndrome: A single centre prospective study

Attenuated Levels of Surface TREM1 on Circulating Neutrophils Predict Poor Survival in Patients with Diffuse Large B-Cell Lymphoma before Treatment

Long-Term Real-World Follow-up Study of Luspatercept for Lower-Risk Myelodysplastic Neoplasms

Effective Treatment of Refractory Aplastic Anemia with Romiplostim after Failure of Multiple Thrombopoietin Receptor Agonists: A Single-Center Retrospective Study

A Phase I First-in-Human, Open-Label Trial to Investigate the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of SIM0500, a Humanized GPRC5D-BCMA-CD3 Trispecific Antibody, in Participants with Relapsed or Refractory Multiple Myeloma

KP104, a Bifunctional C5 Mab-Factor H Fusion Protein, Demonstrates Sustained Long-Term Efficacy and Safety in Complement Inhibitor-Naïve PNH Patients: Updated Results from a Phase 2 Study at 36/38 Weeks of Obd Treatment

Transcriptomic Profile of Peripheral Blood Mononuclear Cells in Sirolimus-Sensitive Acquired Pure Red Cell Aplasia Patients

Ratio of Circulating CD8 + T Lymphocytes to M-MDSCs (CD8MMR): A Novel Prognostic Predictor for Treatment-Naïve DLBCL Patients

The Change of Complement Deposition after Complement Inhibitor Treatment in Paroxysmal Nocturnal Hemoglobinuria Patients

KP104, a Bifunctional C5 Antibody/Factor H Fusion Protein, Effectively Controls Both Intravascular and Extravascular Hemolysis: Interim Results from a Phase 2 Study in Complement Inhibitor-Naïve PNH Patients

Rituximab Plus Bortezomib for Refractory and Relapsed Warm Autoimmune Hemolytic Anemia：a Prospective, Single-Arm, Phase Ⅱ Trial

Myc Translocation Is an Adverse Factor Redefining High-Risk Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only